CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, develops anti-cancer drug candidates for the treatment of brain and central nervous system (CNS) tumors.
The companyâs drug candidates include TPI 287 and Berubicin, which are in Phase 2 clinical trial for the treatment of glioblastoma and other CNS malignancies.
It has license agreement with Cortice Biosciences, Inc. The company was incorporated in 2017 and is headquartered in Houston, Texas.
Founded
2017
Employees
5
Headquarters
Houston, Texas, United States
Website
Loading company sections...
⚡
Core Efficiency
D/E Ratio?
0.25
📊
Profitability Ratios
Current Ratio?
4.94
Loading comparison...
Earnings Calendar
Filing history and next expected filing date
Apr 30, 2025
10-K/AQ4 202430d after period end
Data Freshness
Financial Data
1mo ago
Latest filing: 2026-03-31
SEC Metadata
2mo ago
Latest filing: 2025-11-14
Recent Insider Trades
Charles Faith L. — Purchase 7,100 shares at $4.79 on 2026-05-18
O'Loughlin Steve — Purchase (Derivative) 9,500 shares on 2026-03-02
Levin Rami — Purchase (Derivative) 19,000 shares on 2026-01-01
Gumulka Jerzy — Purchase (Derivative) 1,517 shares at $0.00 on 2025-11-17
